OncologyImmunotherapy lifts four-year cervical cancer survival to 40%
Final BEATcc results show adding atezolizumab to chemotherapy and bevacizumab extended median survival by 9.2 months in advanced cervical cancer, after almost five years of follow-up.
24 October 2026